These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 28140098)

  • 1. Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma.
    Warren TL; Weiner GJ
    Semin Oncol; 2002 Feb; 29(1S2):93-97. PubMed ID: 28140098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma.
    Warren TL; Weiner GJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):93-7. PubMed ID: 11842395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma.
    Warren TL; Dahle CE; Weiner GJ
    Clin Lymphoma; 2000 Jun; 1(1):57-61. PubMed ID: 11707814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
    Wooldridge JE; Ballas Z; Krieg AM; Weiner GJ
    Blood; 1997 Apr; 89(8):2994-8. PubMed ID: 9108420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
    van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
    Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in the treatment of diffuse large B-cell lymphomas.
    Coiffier B
    Semin Oncol; 2002 Feb; 29(1S2):30-35. PubMed ID: 28140089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab: Mechanism of action and resistance.
    Maloney DG; Smith B; Rose A
    Semin Oncol; 2002 Feb; 29(1S2):2-9. PubMed ID: 28140087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
    Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
    Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.
    Weiner GJ
    Adv Drug Deliv Rev; 2009 Mar; 61(3):263-7. PubMed ID: 19168102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens.
    Jahrsdörfer B; Hartmann G; Racila E; Jackson W; Mühlenhoff L; Meinhardt G; Endres S; Link BK; Krieg AM; Weiner GJ
    J Leukoc Biol; 2001 Jan; 69(1):81-8. PubMed ID: 11200072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
    Leonard JP; Link BK
    Semin Oncol; 2002 Feb; 29(1S2):81-86. PubMed ID: 28140096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors.
    Mason KA; Neal R; Hunter N; Ariga H; Ang K; Milas L
    Radiother Oncol; 2006 Aug; 80(2):192-8. PubMed ID: 16905212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia.
    Nabhan C; Rosen ST
    Semin Oncol; 2002 Feb; 29(1S2):75-80. PubMed ID: 28140095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M
    Semin Oncol; 2002 Feb; 29(1S2):70-74. PubMed ID: 28140094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG oligodeoxynucleotides as immunotherapy in cancer.
    Jahrsdörfer B; Weiner GJ
    Update Cancer Ther; 2008 Mar; 3(1):27-32. PubMed ID: 19255607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer.
    Jahrsdörfer B; Weiner GJ
    Semin Oncol; 2003 Aug; 30(4):476-82. PubMed ID: 12939716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab: Ongoing and future clinical development.
    Grillo-López AJ; Hedrick E; Rashford M; Benyunes M
    Semin Oncol; 2002 Feb; 29(1S2):105-112. PubMed ID: 28140083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.